BioWorld1d
New fighter entering the arenavirus arena
Researchers from Emory University, the U.S. CDC and collaborators have identified a broad-spectrum antiviral agent able to combat highly pathogenic arenaviruses. The compound, a ribonucleoside ...
BioWorld2d
Proximity-activated antibody-cytokine fusion protein reinvigorates tumor-specific PD-1-expressing T cells
Researchers from Anaveon AG and affiliated organizations presented the discovery and preclinical characterization of ANV-700, a novel proximity-activated cytokine (PAC) compound designed to ...
BioWorld2d
Oita University divulges new compounds to treat SARS-CoV-2
Oita University has synthesized tricyclic heterocyclic compounds reported to be useful for the treatment of SARS-CoV-2 infection (COVID-19).
BioWorld2d
New CBLB inhibitors disclosed in Inventisbio patent
Scientists at Inventisbio Co. Ltd. and Inventisbio LLC have divulged E3 ubiquitin-protein ligase CBL-B (CBLB) inhibitors reported to be useful for the treatment of cancer.
BioWorld2d
BioWorld Premium
Coronavirus Artificial intelligence Premium reports BioWorld Financings Reports Disease Incidence & Prevalence Summaries sign in Sign Out My Account Subscribe BioWorld - Friday, November 29, 2024 Home ...
BioWorld3d
Allogene’s ALLO-329 shows efficacy at killing CD19- and CD70-expressing cells
To address limitations with CAR T therapies targeting CD19, Allogene Therapeutics Inc. has developed ALLO-329, a ...
BioWorld3d
Dual-targeted approach for hepatobiliary diseases presented
Rectify Pharmaceuticals Inc. has conducted preclinical testing on RTY-694, an oral dual-targeted positive functional ...
BioWorld3d
Pattern Computer advances target and drug discovery in aggressive and early-onset colorectal cancer
The company analyzed genomic data provided by the Fred Hutch Cancer Center and compiled by the Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO) to identify mutational signatures and ...
BioWorld3d
Grant supports Revir’s work in spinal and bulbar muscular atrophy
The collaboration aims to identify a small molecule that targets mutant androgen receptor (AR) mRNA splicing and causes selective destruction of the disease-causing mRNA.
BioWorld3d
E-Therapeutics’ B4GALT1-targeting Galomic siRNA demonstrates prolonged duration of action
Potent siRNAs against B4GALT1 were designed in silico and screened in vitro (Huh7 cells, primary mouse, human hepatocytes) as well as in vivo (C57BL/6 mice) for the selection of a lead Galomic siRNA.
BioWorld3d
BM-205 cell-based gene therapy produces antitumor memory effect
Researchers from SL Bigen Inc. and collaborators presented the preclinical characterization of BM-205, a novel entity of engineered MSCs designed to exert antitumor functions.
BioWorld3d
Beijing Danatlas Pharmaceutical Technology patents new WRN inhibitors
Beijing Danatlas Pharmaceutical Technology Co. Ltd. has disclosed Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors reported to be useful for the treatment of cancer.